Direct Oral Anticoagulant Drugs in Dental Clinical Practice

Open access

Abstract

The direct oral anticoagulant drugs (DOAC) are generally safe and effective in several clinical settings including acute venous thromboembolic disease, prophylaxis in the postoperative setting, prevention of thromboembolism in patients with non-valvular atrial fibrillation, and in the management of acute coronary syndrome. The relatively short half-life, rapid onset of action, and predictable pharmacokinetics should simplify periprocedural use of the DOAC. The aim of this work is to propose and summarize periprocedural management of patients treated with the DOAC in dental practice and to inform about the principal specifications of this treatment.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Schulman S. Advantages and limitations of the new anticoagulants. J Int Med 2014; 275(1): 1-11.

  • 2. Sorensen SV Kansal AR Connolly S et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. J Thromb Haemost. 2011;105(5):908-19.

  • 3. Connolly SJ Ezekowitz MD Yusuf S et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.

  • 4. Patel MR Mahaffey KW Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fi brillation. N Engl J Med 2011; 365:883-891.

  • 5. Cohen AT Spiro TE Buller HR et al; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368:513-523.

  • 6. Hirsh J O'Donnell M and Weitz JY.New anticoagulants. Blood 2005; 105:453-463.

  • 7. Pradaxa 150 mg cps dur. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf

  • 8. Xarelto 10 mg tbl flm. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf

  • 9. Eliquis 5 mg tbl flm. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf

  • 10. Geerts B. The Role of Warfarin in the Era of New Oral Anticoagulants. The 9th International Winter Arrhythmia School Collingwood February 12 2012. Available at: www.winterarrhythmia.com [cit.2015-04-07].

  • 11. Raval AN Cigarroa JE Chung MK. Management of Patients on Non-Vitamin K Antagonist Oral Anticoagulants in the Acute Care and Periprocedural Setting. A Scientific Statement From the American Heart Association. Circulation. 2017;135(10) : e604-e633. DOI: 10.1161/CIR. 0000000000000477. Available at: http://circ.ahajournals.org/content/135/10/e604.long [cit.2015-04-07].

  • 12. Connolly G Spyropoulos AC. Practical issues limitations and periprocedural management of the NOAC’s. J Thromb Thrombolysis 2013; 36:212-222.

  • 13. vanRyn J Stangier J Haertter S et al. Dabigatran etexilate - a novel reversible oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103 (6):1116-1127.

  • 14. Spyropoulos AC Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery? Blood 2012; 120 (15):2954-2962.

  • 15. Fawole A Daw HA Crowther MA. Practical management of bleeding due to the anticoagulants dabigatran rivaroxaban and apixaban. Clev Clin J Med 2013; 80 (7):443-451.

  • 16. UC Davis Health System Anticoagulation Services Recommendations for anticoagulation management before and after dental procedures Approved by UCDHS Pharmacy and Therapeutics Committee 6/2015. Available at: https://www.ucdmc.ucdavis.edu/anticoag/pdf/AnticoagDentalProcedure.pdf [cit.2015-04-07].

  • 17. Ballantyne S. Guidenline for managing patients on Rivaroxaban (XareltoR) 2013 Available at: http://www.health.qld.gov.au./qhcss/mapsu/documents/dabigatran_info.pdf [cit.2015-04-07].

  • 18. Douketis JD Spyropoulos AC Spencer FA et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e326S-50S.

  • 19. Mingaro-De-Leon A Chaveli-Lopez B. Alternative to oral dicoumarin anticoagulants: Consideration in dental care. Journal of clinical and experimental dentistry 2013; 5(5):273-278.

  • 20. Randall C. MWMIC Medicines FAQ. New oral anticoagulants (NOACs) and management of dental pa - tients - Dabigatran rivaroxaban and apixaban. Dental Clinical Guidance. May 2013 Updated Nov 2013. Available at: www.eryldc.co.uk [cit.2015-04-07].

  • 21. Wahl MJ. Myths of dental surgery in patients receiving anticoagulant therapy. J Am Dent Assoc 2000; 131:77-81.

  • 22. Israels S Schwetz N Boyar R et al. Bleeding Disorders: Characterization Dental Considerations and Management. Can Dent Assoc 2006; 72(9):827.

Search
Journal information
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 247 131 8
PDF Downloads 105 62 2